Diagnostic Strategies for Ebola Virus Detection
Shuo Su,Gary Wong,Xiangguo Qiu,Gary P. Kobinger,Yang Bi,Jiyong Zhou
DOI: https://doi.org/10.1016/s1473-3099(16)00049-9
2016-01-01
Abstract:Mobile laboratories for highly dangerous pathogens were deployed in west Africa during the 2014–16 outbreak of Ebola virus disease. These laboratories have substantially reduced the burden on medical professionals by providing on-site diagnostics.1Mansuy JM Mobile laboratories for Ebola and other pathogens.Lancet Infect Dis. 2015; 15: 1135Summary Full Text Full Text PDF Scopus (11) Google Scholar One study estimated that if 60% of patients with Ebola virus disease are diagnosed within 1 day of symptom onset, instead of the current average of 5 days, the virus attack rate drops from 80% to nearly 0%.2Dhillon RS Srikrishna D Garry RF Chowell G Ebola control: rapid diagnostic testing.Lancet Infect Dis. 2015; 15: 147-148Summary Full Text Full Text PDF PubMed Scopus (36) Google Scholar This finding emphasises the substantial effect of a rapid, accurate, clinical diagnosis of Ebola virus disease supported by laboratory tests. Several diagnostic assays were authorised by the US Food and Drug Administration (FDA) for emergency use during the outbreak (appendix). Here, we analyse the use of the three kits that were also approved by WHO (table): RealStar Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany),3WHOWHO emergency quality assessment mechanism for EVD IVDs. Public report. Product: RealStar® Filovirus Screen RT-PCR Kit 1.0.http://www.who.int/diagnostics_laboratory/procurement/141125_evd_public_report_altona_v1.pdf?ua=1Date: 2014Google Scholar ReEBOV Antigen Rapid Test Kit (Corgenix, Broomfield, CO, USA),4WHOWHO emergency use assessment and listing for Ebola Virus Disease IVDs. Public report. Product: ReEBOVTM Antigen Rapid Test Kit.http://www.who.int/diagnostics_laboratory/procurement/150219_reebov_antigen_rapid_test_public_report.pdf?ua=1Date: 2015Google Scholar and Xpert Ebola Assay (Cepheid AB, Sunnyvale, CA, USA).5WHOWHO emergency use assessment and listing for EVD IVDs. Public report. Product: Xpert® Ebola Assay.http://www.who.int/medicines/ebola-treatment/150508FinalPublicReportExpertEbola_Cepheid.pdf?ua=1Date: 2015Google ScholarTableAssays for detecting filovirus infections approved for emergency use by the US FDA and WHOManufacturerDetection techniqueViruses detectedTarget viral geneTime to resultsLimit of detectionPatient specimen neededRealStar Filovirus Screen RT-PCR Kit 1.0 (Nov 2014)3WHOWHO emergency quality assessment mechanism for EVD IVDs. Public report. Product: RealStar® Filovirus Screen RT-PCR Kit 1.0.http://www.who.int/diagnostics_laboratory/procurement/141125_evd_public_report_altona_v1.pdf?ua=1Date: 2014Google ScholarAltona Diagnostics GmbHRT-qPCREbola virus, Sudan virus, Reston virus, Tai Forest virus, Bundibugyo virus, Marburg virusL4–6 h (negative), less for a positive1 plaque-forming unit (about 3400 copies) of Ebola virus or Sudan virus per mL plasmaPlasma collected in EDTA, cell-free bodily fluids, swab washesReEBOV Antigen Rapid Test (Feb 2015)4WHOWHO emergency use assessment and listing for Ebola Virus Disease IVDs. Public report. Product: ReEBOVTM Antigen Rapid Test Kit.http://www.who.int/diagnostics_laboratory/procurement/150219_reebov_antigen_rapid_test_public_report.pdf?ua=1Date: 2015Google ScholarCorgenixRapid chromatographic immunoassayEbola virusVP4015–25 min2·11 × 108 RNA copies per mL (extrapolated) or 1 × 108 plaque-forming units per mL (FDA calculated)Finger-prick (capillary) whole blood, venous whole blood, or plasma collected in EDTAXpert Ebola Assay (May 2015)5WHOWHO emergency use assessment and listing for EVD IVDs. Public report. Product: Xpert® Ebola Assay.http://www.who.int/medicines/ebola-treatment/150508FinalPublicReportExpertEbola_Cepheid.pdf?ua=1Date: 2015Google ScholarCepheid ABRT-qPCREbola virusNucleoprotein and glycoprotein90 min82·0 RNA copies per reaction (95% CI 39·7–3193·6)Venous whole blood collected in EDTAFDA=Food and Drug Administration. Open table in a new tab FDA=Food and Drug Administration. The RealStar device is a real-time quantitative PCR (RT-qPCR) test for detecting the L gene. The device takes 4–6 h to provide a negative result, roughly 2 h for a positive result, and has a limit of detection of 1 plaque-forming unit per mL, or about 3400 copies per mL. ReEBOV is a rapid chromatographic immunoassay against VP40; it takes 15–25 min to produce a final result and has a limit of detection of 2·11 × 108 copies per mL (by extrapolation), or 1 × 106 plaque-forming units per mL (FDA calculated6US Food and Drug AdministrationReEBOVTM Antigen Rapid Test (Ebolavirus VP40 antigen detection). Instructions for use.http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM438511.pdfDate: 2015Google Scholar). The Xpert Ebola Assay is an RT-qPCR test for detecting viral nucleoprotein and glycoprotein. The assay takes 90 min to produce results and has a limit of detection of 82·0 RNA copies per reaction. The ReEBOV test was used in two clinics in Sierra Leone during the Ebola outbreak and was found to be 100% specific for Ebola.7Broadhurst MJ Kelly JD Miller A et al.ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.Lancet. 2015; 386: 867-874Summary Full Text Full Text PDF PubMed Scopus (133) Google Scholar Cycle threshold values of the tested patients ranged from 15·9 to 26·3 (mean 22·6).7Broadhurst MJ Kelly JD Miller A et al.ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.Lancet. 2015; 386: 867-874Summary Full Text Full Text PDF PubMed Scopus (133) Google Scholar However, at these values, most patients will be showing clinical signs of moderate to severe Ebola virus disease, and values less than 20 are associated with terminal disease. Rapid diagnostic tests are also important for detecting and confirming infected patients who have not yet progressed to advanced disease (cycle threshold >30), at a time when they are less infectious to others, and with a greater chance of survival with clinical intervention. The high limit of detection suggests that the ReEBOV test is currently not sufficiently sensitive to optimally inform and manage suspect cases or outbreaks. Rather, in view of the quick turnaround time, the test is more applicable for rapid screening of patients with advanced disease, in whom a positive result would raise the alarm and push for confirmation by RT-qPCR and next-generation sequencing. RT-qPCR-based assays have a lower limit of detection; however, the longer turnaround time plus the time needed for viral RNA extraction suggests that the RealStar test and the Xpert Ebola Assay are better suited to confirmation or diagnosis of suspected cases early after onset of Ebola virus disease. Future research efforts should prioritise lowering the limit of detection of assays based on RT-qPCR to improve diagnostics for Ebola and detect and manage potential outbreaks at the earliest opportunity. This report was partly supported by the National Key Program for Infectious Disease of China (2016ZX10004222-011), the National Key Technology R&D Program of China (2015BAD12B00), the National Natural Science Foundation of China (81590760), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Special Foundation of President for Ebola virus research from Chinese Academy of Sciences. GW is the recipient of a Banting Postdoctoral Fellowship from the Canadian Institutes of Health Research and the President's International Fellowship Initiative from the Chinese Academy of Sciences. We declare no competing interests. Download .pdf (.2 MB) Help with pdf files Supplementary appendix Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyThe emergence of MCR-1 heralds the breach of the last group of antibiotics, polymyxins, by plasmid-mediated resistance. Although currently confined to China, MCR-1 is likely to emulate other global resistance mechanisms such as NDM-1. Our findings emphasise the urgent need for coordinated global action in the fight against pan-drug-resistant Gram-negative bacteria. Full-Text PDF